GNF-5, with the CAS number 778277-15-9, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of certain protein kinases. It is characterized by its ability to modulate specific signaling pathways, which can have implications in cancer research and treatment. The compound typically exhibits a high degree of specificity, minimizing off-target effects, which is crucial for therapeutic applications. GNF-5 is often studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for determining its viability as a drug candidate. Additionally, its chemical structure may include functional groups that enhance solubility and bioavailability. As with many compounds in drug development, ongoing research aims to elucidate its mechanism of action, potential side effects, and overall efficacy in clinical settings. Understanding these characteristics is vital for advancing its application in targeted therapies.

GNF-5

778277-15-9: GNF-5, with the CAS number 778277-15-9, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of certain protein kinases. It is characterized by its ability to modulate specific signaling pathways, which can have implications in cancer research and treatment. The compound typically exhibits a high degree of specificity, minimizing off-target effects, which is crucial for therapeutic applications. GNF-5 is often studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for determining its viability as a drug candidate. Additionally, its chemical structure may include functional groups that enhance solubility and bioavailability. As with many compounds in drug development, ongoing research aims to elucidate its mechanism of action, potential side effects, and overall efficacy in clinical settings. Understanding these characteristics is vital for advancing its application in targeted therapies.

<p>GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.</p>

CAS 778277-15-9

GNF-5

GNF-5

Ref: 54-BUP15100

GNF-5

Ref: TM-T1803

GNF-5

Ref: 10-F857124